Achieving the world's first indication for the long-acting growth hormone ISS, changchun high-tech industries' revenue and net profit decline situation resolved? | Speed read announcement
On the 5th, changchun high-tech industries announced that its long-acting growth hormone has been approved for ISS indications, and in August this year, the variety was also approved for growth disorders in girls caused by gonadal dysgenesis (Turner syndrome). In the first three quarters of this year, changchun high-tech industries recorded a decline in performance and profits. Whether the main products that have been on the market for 10 years will have additional volumes is widely anticipated.
Shandong pharmaceutical glass: October sales performance better than Q3 average level, current overall costs remain relatively stable | Direct hit earnings conference
①Regarding the situation in Q4, Zhang Jun, the General Manager of shandong pharmaceutical glass, stated that the declining business in Q3 has shown some improvement. According to the current situation, it is expected that Q4 will be better than Q3; ②In terms of costs, while the price of the main raw material caustic soda has decreased, energy prices have risen, resulting in overall costs remaining stable.
Shenzhen Mindray Bio-Medical Electronics Q3 net income fell by 9.31% due to factors such as delayed hospital purchases and sluggish non-rigid medical demand. | Financial report
Affected by factors such as delayed hospital procurement, tight hospital construction funds, and low non-rigid medical demand, in the third quarter, Shenzhen Mindray Bio-Medical Electronics' net income decreased by 9.31% year-on-year, while total revenue increased by 1.43% year-on-year. In the second interim profit distribution for 2024, Shenzhen Mindray Bio-Medical Electronics will distribute 16.50 yuan for every 10 shares.
Foreign public fund latest hold positions exposure! Fund managers are bullish on china's stock market valuation repair.
With the disclosure of the third quarter report, public funds under international asset management giants such as BlackRock and Fidelity have all their holdings exposed.
R&D expenses continue to rise, autobio diagnostics once again embroiled in a whirlpool of disputes | interpretations
①In the first three quarters of this year, the revenue and net income attributable to shareholders of Autobio Diagnostics have both increased to a certain extent; ②The company has further increased its investment in research and development, with multiple products obtaining medical instruments registration certificates.
Decreased sales of the herpes zoster vaccine dragged down Baik biological's third-quarter revenue by more than 40%.
1. Due to the decrease in sales of the live attenuated herpes zoster vaccine, Baik Bio's third-quarter revenue decreased by 40.37% year-on-year, while net income attributable to shareholders decreased by 51.41%; 2. Currently, in addition to GSK's herpes zoster vaccine competing with Baik Bio in the domestic market, there are also over 10 companies developing similar products, posing multiple potential competitors for Baik Bio.